Nerve agent

Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote

Retrieved on: 
Thursday, January 12, 2023

Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.

Key Points: 
  • Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
  • Nerve agents kill brain cells leading to respiratory failure, seizures, and death within minutes of exposure.
  • Previous work in humans completed by Odyssey has shown that intranasal administration of spray-dried powders leads to low plasma concentrations compared to an intravenous route.
  • Oximes are an antidote for organophosphate nerve agents however the current application is through a skin auto-injector.

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Retrieved on: 
Friday, July 23, 2021

"We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.

Key Points: 
  • "We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.
  • Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may disrupt the transfer of messages to organs through the nerves.
  • These same receptors are the target of Nutra Pharmas drugs, which may block the action of the nerve agents or minimize the damage that they may cause.
  • Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death.

Kentucky plant begins nerve-agent rocket destruction campaign

Retrieved on: 
Tuesday, July 13, 2021

RESTON, Va., July 13, 2021 /PRNewswire/ --A Bechtel-led plant in Kentucky has successfully begun destroying its next batch of chemical weapons, just two months after completing a previous campaign.

Key Points: 
  • RESTON, Va., July 13, 2021 /PRNewswire/ --A Bechtel-led plant in Kentucky has successfully begun destroying its next batch of chemical weapons, just two months after completing a previous campaign.
  • The first M55 rockets containing VX nerve agent were destroyed July 9 at the Blue Grass Chemical Agent-Destruction Pilot Plant (BGCAPP), near Richmond, Kentucky.
  • "Our team has successfully completed two projectile campaigns involving nerve agent," said Ron Hink, Bechtel Parsons Blue Grass project manager.
  • "As with previous campaigns, safety will remain the top priority as we begin rocket destruction."

Kentucky plant completes destruction of VX nerve agent weapons in just 4 months

Retrieved on: 
Wednesday, June 2, 2021

The current campaign focused on the eradication of approximately 60 tons of VX nerve agent in 155-milimeter artillery projectiles, which were opened and drained robotically.

Key Points: 
  • The current campaign focused on the eradication of approximately 60 tons of VX nerve agent in 155-milimeter artillery projectiles, which were opened and drained robotically.
  • The drained toxins undergo a neutralization process using hot water and sodium hydroxide to destroy the VX agent.
  • The Blue Grass Chemical Agent-Destruction Pilot Plant is safely destroying more than 523 tons of mustard and nerve agent in rockets and projectiles.
  • Additionally, the main plant destroyed the remaining stockpile of eight-inch nerve agent projectiles, eliminating another class of weapon from the U.S. stockpile.

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

Retrieved on: 
Tuesday, May 11, 2021

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.

Key Points: 
  • b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.
  • The therapy was shown to be effective even with delayed use following nerve agent exposure.
  • Currently, treatment for OP exposure is with an anticholinergic agent administered immediately after exposure; thus, military personnel may receive kits containing atropine auto-injectors for use in the event of a nerve-gas attack.\nDr.
  • Importantly, this new combination therapy also extends the therapeutic window, as it is effective even when administered hours after OP exposure.

Kentucky Plant Begins Destruction of Next Inventory of Nerve Agent Weapons

Retrieved on: 
Tuesday, January 12, 2021

At the Blue Grass Chemical Agent-Destruction Pilot Plant in Richmond, a 155-milimeter artillery projectile filled with VX nerve agent was robotically opened and drained on Jan. 10.

Key Points: 
  • At the Blue Grass Chemical Agent-Destruction Pilot Plant in Richmond, a 155-milimeter artillery projectile filled with VX nerve agent was robotically opened and drained on Jan. 10.
  • "The Chemical Weapons Convention commits more than 190 nations to the eradication of these weapons.
  • In early 2020, the plant destroyed the remaining stockpile of 8-inch nerve agent projectiles, eliminating an entire class of weapon from the U.S. stockpile.
  • After the current campaign, an inventory of rockets containing nerve agent will be all that remains.

Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure

Retrieved on: 
Monday, September 14, 2020

RSE can occur as a result of a variety of serious, acute medical conditions or after exposure to nerve agents.

Key Points: 
  • RSE can occur as a result of a variety of serious, acute medical conditions or after exposure to nerve agents.
  • Under the contract, Marinus will be responsible for cost-sharing in the amount of $33 million if all development options are completed.
  • Through this contract, we are demonstrating our commitment to develop innovative anticonvulsant agents, and we believe this funding will help to strengthen our ganaxolone franchise.
  • On a successful development, BARDA and Marinus may negotiate a procurement agreement for a supply of ganaxolone for potential response to nerve gas exposure threats.

U.S. Army Awards $21.8M Production Contract to FLIR Systems for Nerve Agent Disclosure Spray

Retrieved on: 
Thursday, July 16, 2020

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has been awarded a full-rate production option worth $21.8 million on an indefinite-delivery/ indefinite-quantity (IDIQ) contract with the United States (U.S.) Army.

Key Points: 
  • FLIR Systems, Inc. (NASDAQ: FLIR) announced it has been awarded a full-rate production option worth $21.8 million on an indefinite-delivery/ indefinite-quantity (IDIQ) contract with the United States (U.S.) Army.
  • FLIR will deliver its Agentase C2 disclosure spray to detect G- and V-series nerve agents, highly toxic chemical warfare agents.
  • (Photo: Business Wire)
    FLIR Agentase C2 spray quickly changes color on a surface if a chemical warfare agent is present.
  • In September 2019, FLIR announced a $35.1 million contract with the U.S. Army to deliver its disclosure spray formulated for blister agents such as sulfur mustard.

SwRI Receives $9.9 Million to Develop Nerve Agent Antidote

Retrieved on: 
Tuesday, March 24, 2020

Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.

Key Points: 
  • Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.
  • This prototype medication could serve as a countermeasure against a nerve agent attack.
  • SwRI will lead the development of the antidote under the $9.9 million, five-year program, and will collaborate with University of Pittsburgh on the synthesis and compound design, through the support of the Defense Threat Reduction Agency (DTRA).
  • The antidote will eventually be administered through an autoinjector, which allows for rapid and effective treatment in the field.